SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Matritech (NASDAQ - NMPS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: eugenic1 who wrote (73)6/13/1996 10:09:00 PM
From: Tim Zhu   of 849
 
Yeah! 2M shares by one of the best underwriter --- Montgomery.

According to the press release, 17.8M shares will be the outstandiing shares after PPO. But I don't know how many will be the floating.

Maybe this is the reason why it stayed in the low price these days since the shareholder meeting ten days ago. I guess PPO date should be after FDA approval so that NMPS can be benifit more. So FDA approval shold be very near.

or, if PPO is before FDA approval, the stock price will go up to get more fund for Matritech. And more, the market maker no more need to drop the price to feed the big institutions. ( institution holding was increase from 37% to 43% recently )

Since Montgomery is going to involve in Matritech's PPO, the stock price should be raised and supported in a certain level. -- Just my opinion.

I am not that positive in BMRA. CELI is good but I did't follow. BTW, look at BTGC today, up with big volume! BTGC will have a good earning report this quarter. (End of July)

Regards.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News